Pfizer signaled Tuesday it expects a challenging 2026 as it invests in new products to offset declines in Covid-19 revenues ...

The company now expects full year 2025 guidance of about $62 billion, to the lower end of its previous guidance of $61 to $64 billion and below an analyst estimate of $62.52 billion.

Amid profit forecast reductions, Pfizer is implementing a $7.7bn cost-cutting strategy, while investing into its ...

Pfizer said on Tuesday the next few years will be bumpy, beginning with 2026, due to lower sales of its COVID vaccine and ...

The large impact of school closures on children’s mental health may stem from changes in social interaction, disrupted sleep, ...

Neoantigen vaccines are at the forefront of cancer research, driving personalized immunotherapy and improving outcomes ...

The UKHSA will carry out work to strengthen the UK’s pandemic preparedness, vaccine delivery and AMR response over the next ...

AI-driven research has produced nasal antivirals that block flu and Covid before cell infection, pointing to new prevention ...

From Haffkine and Sokhey, to polio, BCG, and COVID, Ameer Shahul reflects on science, ethics, colonial power and the rise of ...

Now, the Lundquist Institute (TLI) and Vitalex Biosciences announce that they will move forward in the development of the second-generation fungal vaccine candidate known as VXV‑01—up to and including ...

As we prepare for the festive season, it’s easy to let COVID boosters fall off our to-do lists. But COVID is still circulating and new shots are available.

A rapid, two-step immune reaction may underlie rare cases of heart inflammation seen after COVID-19 mRNA vaccination, ...